Hyperion DeFi, Inc.(HYPD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.58
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HYPD

11/13/2026: HYPD (1-star) is currently NOT-A-BUY. Pass it for now.

Hyperion DeFi, Inc. is a digital asset treasury and decentralized finance operating company that provides public markets with exposure to the Hyperliquid ecosystem alongside legacy ophthalmic assets. The company's main strengths include a debt-free balance sheet, active capital optimization, and innovative DeFi yield generation strategies that outperform passive token holding. Its primary investment growth story centers on capturing high-growth decentralized finance infrastructure returns and scaling institutional credit facilities. Key risks involve high price volatility tied to digital asset markets, thin trading liquidity, and evolving regulatory frameworks surrounding cryptocurrency. The stock suits risk-tolerant growth investors seeking crypto-adjacent exposure while monitoring ongoing treasury execution and network adoption metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers direct exposure to high-growth decentralized finance trends and scaling blockchain infrastructure.
Momentum investorStrong fit while signal remains positiveStock price action tracks digital asset volatility closely, creating potential momentum-driven trading windows.
Value investorWeak fitValuation relies heavily on digital asset market sentiment rather than traditional discounted cash flow metrics.
Dividend investorWeak fitThe company does not pay dividends, directing cash flow into growth and treasury accumulation.
Low-risk investorWeak fitSubstantial price volatility and exposure to digital asset markets introduce high risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighShares experience sharp fluctuations driven by cryptocurrency market sentiment and token price swings.
Valuation riskMedium / highValuation models depend heavily on the fluctuating net asset value of digital treasury holdings.
Competition risk (digital asset treasury & DeFi competition)MediumThe firm competes with alternative digital asset investment vehicles and crypto-holding operating entities.
Business qualityMediumThe operating model is novel and transitioning rapidly from its historical biotechnology roots.
Dividend incomeLow / noneNo dividend yield is offered to investors seeking recurring income.
Execution riskMedium / highSuccess depends on effective management of decentralized finance strategies and blockchain infrastructure.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 39.84M USD
Price to earnings Ratio -
1Y Target Price 9.82
Price to earnings Ratio -
1Y Target Price 9.82
Volume (30-day avg) 259.3K shares
Beta 2.74
52 Weeks Range 2.34 - 5.14
Updated Date 11/15/2026
52 Weeks Range 2.34 - 5.14
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -6.46

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -57.9%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HYPD receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
HYPD has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, moderate earnings growth (+9.0%) and strong revenue growth (+1318.8%) are partially offset by weak cash generation (FCF margin -1815.7%), weak profitability (net margin -5570.6%).

Financial Health Rating

★★★★★
HYPD's financial health is soft, with the relatively strongest area being soft efficiency, including operating-expense and cost-of-revenue discipline (opex 2396.1% of revenue). Overall financial-health metrics support a 2-star score.

Growth Momentum Score

★★★★★
Revenue growth is HYPD's strongest growth driver at +1318.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+51.2%, strong) is also strong, while earnings growth (+9.0%, moderate) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 19.8% (soft) and 89.0% of outstanding shares are publicly tradable (strong). Insider ownership of 5.33% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 3.07%
Franklin Templeton Inc 2.60%
Arrington Capital Management, LLC 1.96%
Morgan Stanley - Brokerage Accounts 1.57%
Almanack Investment Partners, LLC. 1.11%

Unit Economics (Per $1K Revenue)

★★★★★
HYPD generates approximately $627 of gross profit, $-23,334 of operating income, and $-18,157 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
HYPD has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Digital Assets & DeFi OperationsStaking rewards, validator operations, ecosystem yield generation, and institutional credit facilities tied to the Hyperliquid blockchain.Generates revenue through active participation in decentralized finance ecosystems rather than traditional product sales.
Ophthalmic TechnologyLegacy development and licensing of ophthalmic drug delivery systems like the Optejet device.Represents a legacy healthcare segment with potential milestone or licensing upside.

Earnings Date

Report Date 2026-11-12
When Before Market
Estimate 2.31
Actual 1.23

Profitability

Profit Margin 474.87%
Operating Margin (TTM) -1066.76%

Management Effectiveness

Return on Assets (TTM) -11.06%
Return on Equity (TTM) 9.55%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 39.12M
Price to Sales(TTM) 28.44
Enterprise Value 39.12M
Price to Sales(TTM) 28.44
Enterprise Value to Revenue 27.93
Enterprise Value to EBITDA 5.17
Shares Outstanding 15.44M
Shares Floating 13.75M
Shares Outstanding 15.44M
Shares Floating 13.75M
Percent Insiders 5.33
Percent Institutions 19.75

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.